Drug Profile
Abicipar pegol - Molecular Partners AG
Alternative Names: AGN-150998; Anti-VEGF DARPin®; DARPin® anti-VEGF product for eye disorders - Molecular Partners/AbbVie; MP-0112Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Molecular Partners AG
- Developer AbbVie; Molecular Partners AG
- Class Eye disorder therapies; Polyethylene glycols; Proteins
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Wet age-related macular degeneration
- Discontinued Diabetic macular oedema
Most Recent Events
- 27 Oct 2022 Abicipar pegol - Molecular Partners AG is available for licensing as of 27 Oct 2022. https://www.molecularpartners.com/
- 20 Dec 2021 Discontinued - Phase-II for Diabetic macular oedema in USA, prior to December 2021 (Intravitreous) (Molecular partners AG pipeline, December 2021)
- 09 Aug 2021 AbbVies terminates the licensing and collaboration agreement with Molecular Partners AG for abicipar pegol